Andrew Gaya

Broschiertes Buch

Combination Studies With The Vascular Disrupting Agent CA4P

Clinical Studies combined with chemotherapy and radioimmunotherapy, and DCE-MRI and immunohistochemistry correlation

Beschreibung

This work represents studies carried out at Mount Vernon Hospital and UCL, and sponsored by Cancer Research UK, between 2003 and 2006. Phase I/II Clinical trial studies of the vascular disrupting agent Combretastatin A4 Phosphate (CA4P) are presented - in combination with cytotoxic chemotherapy (Paclitaxel and Carboplatin), and radioimmunotherapy. Dynamic Contrast Enhanced MRI data from the studies is presented and discussed, and a supporting immunohistochemistry correlation study of vascular markers is also presented.

Autor

Dr Gaya is a Clinical Oncologist at Guy's and St Thomas' Hospitals in London. He has completed an MD at UCL of which this work is a summary. He treats patients with GI cancers and is continuing to pursue an interest in functional imaging of cancers.

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Seitenzahl: 256
• Erscheinungstermin: 10. Mai 2011
• Englisch
• Abmessung: 220mm x 150mm x 16mm
• Gewicht: 399g
• ISBN-13: 9783838343532
• ISBN-10: 3838343530
• Artikelnr.: 33373677